Inogen CEO: ‘We continue to make meaningful progress’ Company initiates limited market release of Simeox airway clearance device in US
By HME News Staff
Updated 11:24 AM CST, Thu November 6, 2025
GOLETA, Calif. - Inogen reported $92.4 million in revenue for the third quarter of 2025, a 4% increase year over year.
Other financial results:
- A GAAP net loss of $5.3 million vs. $6 million and adjusted net loss of $0.5 million vs. $2.6 million.
- $2.3 million adjusted EBITDA, the third consecutive quarter of positive adjusted EBITDA
- $2.2 million in positive operating cash flow, strengthening quarter-end cash, cash equivalents, marketable securities and restricted cash to $124.5 million
"We continue to make meaningful progress, driving consistent mid-single-digit revenue growth, operational improvements, and strong adjusted EBITDA," said Kevin Smith, president and CEO. "This quarter’s results reflect the strength of our commercial strategies, financial discipline, and commitment to delivering innovative solutions. Looking forward, we remain focused on building long-term value for our shareholders by advancing Inogen’s leadership in respiratory care."
Inogen also announced that it has initiated a limited market release of the Simeox airway clearance device in the United States.
The company reiterates full-year revenue outlook of $354 million to $357 million and raises adjusted EBITDA guidance to about $2 million.
Comments